Biomedical investment and business development chatter
isis
Osiris Leaps on $1.38 Billion Genzyme Stem-Cell Deal
Genzyme announced that they have entered a strategic alliance for the development and commercialization of Prochymal and Chondrogen, two novel, late-stage adult mesenchymal stem cell treatments that hold significant potential to treat a wide range of diseases. These stem-cell products are designed to provide therapeutic benefit by controlling inflammation, promoting tissue regeneration, and preventing scar [...]
Top Biopharma Deals Q1 ‘08
It’s a just a quarter of the way into 2008 and it is clear the both large
biotech and pharma have holes to fill in thier pipeline. Six deals have
already been inked that total over a half a billion bio-dollars each.
Below are 4 of the top deals thus far:
Genzyme/Isis ($1,900M) - Genzyme paid Isis $175M in
cash [...]
© 2008 Pharmababble. 
Recent Comments